Treating spondyloarthritis early: does it matter? Results from a systematic literature review.
Dafne CapelusnikDiego BenaventDésirée van der HeijdeRobert LandewéDenis PoddubnyyAstrid van TubergenLouise FalzonVictoria Navarro-CompánSofia RamiroPublished in: Rheumatology (Oxford, England) (2022)
Evidence towards better outcomes in early axSpA is very limited and restricted to nr-axSpA and <5 years symptom duration. When early axSpA is defined based on disease duration or radiographic damage, no differences in response to treatment are found.